PCSK9 panels: Nissen's take
This article was originally published in Scrip
Executive Summary
An FDA advisory panel got it right this week when it recommended to approve, but limit the use to certain patient populations, two experimental proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors, said Dr Steven Nissen, chairman of the Department of Cardiovascular Medicine at the Cleveland Clinic Foundation in Ohio and a professor of medicine at Case Western Reserve University.